Notch Ligand Surface-Area Culture for Scalable T Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing feeder cell-based methods for generating T cell lineage cells are heterogeneous and not easily scalable, leading to diverse outcomes and limitations in clinical manufacturing, with no effective control over in vitro emergence of mature T cell lineages or reports of unique phenotypes.
Innovation Solution
A method involving culturing progenitor T cells in the presence of a Notch signaling ligand, such as Delta-like-4 (DL4), on a surface area of at least 7 cm²/mL, often combined with vascular cell adhesion molecule 1 (VCAM-1), to enrich for CD4-CD8+ cells, using three-dimensional substrates like beads made of polystyrene, iron oxide, or gold, and varying concentrations and surface areas to promote CD4-CD8+ T cell lineage development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If feeder cell-based methods are used for generating T cell lineage cells, then T cells can be generated in vitro, but the expression of cell surface proteins by supportive stromal cells is heterogeneous leading to diverse outcomes and poor scalability
Solution Approach 1:
The patent removes feeder cells from the system entirely, extracting the problematic heterogeneous stromal cell component. Instead of using feeder cells to provide Notch signaling, the invention uses defined soluble Notch ligands (DLL1-4) that can be added to culture media, eliminating the source of heterogeneity while maintaining T cell generation capability
Solution Approach 2:
The patent changes the delivery mechanism of Notch signaling from cell-based (feeder cells expressing surface proteins) to molecular-based (soluble ligands in culture media). This parameter change allows precise control over ligand concentration and eliminates the heterogeneity inherent in feeder cell populations, enabling both reliable and scalable T cell generation
2Productivity
If feeder cell-based systems are used, then T cell differentiation can occur, but the systems are not easily scalable to meet clinical manufacturing needs
Solution Approach 1:
By removing feeder cells from the system, the patent eliminates the bottleneck that limited scalability. The feeder cell-based system requires complex co-culture setups that are difficult to scale, whereas the soluble ligand approach uses simple culture vessels that can be easily scaled from research to clinical manufacturing
Solution Approach 2:
The patent enables the culture system to be self-sufficient without requiring feeder cells to provide Notch signaling. The soluble ligands are added directly to the media, creating a self-contained system that can be scaled independently of cell-based support structures, thereby improving ease of manufacture and productivity
3Quantity of substance
If Notch signalling ligands are provided at high surface area concentrations, then CD4-CD8+ cell generation is promoted, but the method complexity increases
Solution Approach 1:
The patent extracts the ligand delivery from complex surface-area-based systems (beads, microcarriers, or feeder cells with high surface area) and simplifies it to soluble ligands added directly to culture media. This reduces device complexity while maintaining the ability to provide sufficient Notch signaling for CD4-CD8+ cell generation
Solution Approach 2:
The patent changes the delivery parameter from surface area concentration (cm²/mL) to volumetric concentration (ng/mL or μg/mL) by using soluble ligands in culture media. This parameter change simplifies the delivery system while maintaining effective ligand availability for Notch signaling, thereby reducing complexity without compromising cell generation efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the production of CD4-CD8+ T cells, including CD8αβ+ cells, which are T cell receptor negative (TCR−/sCD3−), providing a controlled and scalable method for generating mature T cell lineages suitable for clinical applications.
Implementation Method 1
culturing the progenitor T cells in the presence of a Notch signalling ligand provided on a surface area of at least 7 square centimetres per millilitre culture volume (7 cm2/mL)
Implementation Method 2
the Notch signalling ligand is provided on a surface area of 7 to 56 cm2/mL, 7.8 to 55.2 cm2/mL, or 15.7 to 55.2 cm2/mL
Data Source
AI summary
The present disclosure provides a method for generating a T cell lineage population from progenitor T cells. The method comprises culturing the progenitor cells in the presence of Notch signalling ligand, such as Delta-like-4 (DL4), provided on a surface area of at least 7 square centimetres per millilitre culture volume (7 cm2/mL). Population of cells produced using the method are provided as well as methods of using same. Further provided is a method of differentiating a progenitor T cell population enriched for CD4-CD8+ TCRγδ+ cells comprising culturing progenitor T cells in the presence of Notch signalling ligand, such as DL4, provided on a surface area of 0.78 to 4.7 cm2/mL.